Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Stoke Therapeutics, Inc. (NASDAQ:STOK) has been given an average rating of “Moderate Buy” by the eleven brokerages that are currently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $39.1818.

A number of analysts recently weighed in on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Stoke Therapeutics in a research note on Monday, December 29th. Canaccord Genuity Group boosted their price target on shares of Stoke Therapeutics from $28.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, January 5th. Chardan Capital increased their price objective on shares of Stoke Therapeutics from $24.00 to $35.00 and gave the company a “buy” rating in a research report on Monday, January 5th. JPMorgan Chase & Co. raised their price objective on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a report on Monday, November 3rd. Finally, HC Wainwright boosted their target price on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, December 15th.

Stoke Therapeutics Price Performance

Shares of STOK stock opened at $31.99 on Tuesday. Stoke Therapeutics has a 1-year low of $5.35 and a 1-year high of $38.69. The firm has a market cap of $1.83 billion, a PE ratio of 47.75 and a beta of 1.10. The company has a 50-day moving average of $31.50 and a two-hundred day moving average of $26.50.

Insiders Place Their Bets

In other news, insider Barry Ticho sold 3,662 shares of the stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $31.34, for a total value of $114,767.08. Following the transaction, the insider owned 19,798 shares in the company, valued at approximately $620,469.32. This represents a 15.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel Jonathan Allan sold 8,785 shares of the firm’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $31.29, for a total value of $274,882.65. Following the sale, the general counsel directly owned 15,809 shares in the company, valued at $494,663.61. This trade represents a 35.72% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 98,774 shares of company stock valued at $2,918,365. 9.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of STOK. Vanguard Group Inc. raised its stake in Stoke Therapeutics by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock worth $74,351,000 after acquiring an additional 217,616 shares in the last quarter. Marshall Wace LLP grew its holdings in shares of Stoke Therapeutics by 7.9% during the second quarter. Marshall Wace LLP now owns 2,300,554 shares of the company’s stock worth $26,111,000 after purchasing an additional 168,771 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Stoke Therapeutics by 21.4% during the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock worth $11,053,000 after purchasing an additional 293,072 shares in the last quarter. Polar Capital Holdings Plc increased its position in shares of Stoke Therapeutics by 49.8% during the third quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company’s stock worth $31,102,000 after purchasing an additional 439,824 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of Stoke Therapeutics by 36.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,227,723 shares of the company’s stock valued at $38,968,000 after purchasing an additional 327,451 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.